Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
ICPT

ICPT - Intercept Pharmaceuticals Inc Stock Price, Fair Value and News

19.00USD Delayed

Market Summary

ICPT
USD19.00
Delayed

ICPT Stock Price

View Fullscreen

ICPT RSI Chart

ICPT Valuation

Market Cap

794.7M

Price/Earnings (Trailing)

-12.9

Price/Sales (Trailing)

2.5

Price/Free Cashflow

-12.5

ICPT Price/Sales (Trailing)

ICPT Profitability

Operating Margin

99.80%

Return on Equity

-85.76%

Return on Assets

-15.67%

Free Cashflow Yield

-8%

ICPT Fundamentals

ICPT Revenue

Revenue (TTM)

317.7M

Rev. Growth (Yr)

14.44%

Rev. Growth (Qtr)

6.06%

ICPT Earnings

Earnings (TTM)

-61.6M

Earnings Growth (Yr)

-101.04%

Earnings Growth (Qtr)

52.41%

Breaking Down ICPT Revenue

Last 7 days

0.1%

Last 30 days

2.2%

Last 90 days

81.3%

Trailing 12 Months

27.8%

How does ICPT drawdown profile look like?

ICPT Financial Health

Current Ratio

4.22

Debt/Equity

3.12

Debt/Cashflow

-0.28

ICPT Investor Care

Shares Dilution (1Y)

33.79%

Diluted EPS (TTM)

-1.48

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023294.5M306.5M317.7M0
2022262.6M266.2M277.1M285.7M
2021297.3M288.3M275.4M260.8M
2020272.4M283.4M300.9M312.7M
2019196.1M218.8M233.8M252.0M
2018145.9M158.6M164.2M179.8M
201745.6M70.9M107.1M131.0M
20161.8M6.9M11.6M25.0M
20152.8M2.8M2.8M2.8M
20141.6M1.7M1.7M1.7M
20132.1M1.7M1.6M1.6M
20122.6M2.9M2.8M2.4M
20110001.8M

Tracking the Latest Insider Buys and Sells of Intercept Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 08, 2023
miller-rich nancy
back to issuer
-154,109
19.00
-8,111
-
Nov 08, 2023
benatti luca
back to issuer
-154,109
19.00
-8,111
-
Nov 08, 2023
santini gino
back to issuer
-154,109
19.00
-8,111
-
Nov 08, 2023
ford david a
back to issuer
-406,600
19.00
-21,400
chief human resources officer
Nov 08, 2023
miller-rich nancy
sold
-423,776
19.00
-22,304
-
Nov 08, 2023
akkaraju srinivas
sold
-719,853
19.00
-37,887
-
Nov 08, 2023
saik andrew
back to issuer
-859,636
19.00
-45,244
evp & chief financial officer
Nov 08, 2023
venezia rocco
sold
-204,858
19.00
-10,782
chief accounting officer
Nov 08, 2023
akkaraju srinivas
back to issuer
-154,109
19.00
-8,111
-
Nov 08, 2023
venezia rocco
back to issuer
-278,711
19.00
-14,669
chief accounting officer

1–10 of 50

Which funds bought or sold ICPT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
Prospera Financial Services Inc
sold off
-100
-579,567
-
-%
Jan 02, 2024
VIRGINIA RETIREMENT SYSTEMS ET AL
sold off
-100
-619,360
-
-%
Aug 10, 2023
Tekla Capital Management LLC
unchanged
-
-123,399
575,861
0.02%
Aug 10, 2023
PICTET ASSET MANAGEMENT SA
added
37.48
1,233,380
10,562,400
0.01%
Mar 17, 2023
American Portfolios Advisors
reduced
-0.11
3,857
432,450
0.02%
Jul 12, 2022
EXANE DERIVATIVES
new
-
83.00
83.00
-%
May 16, 2022
Amalgamated Financial Corp.
new
-
66,000
66,000
-%
May 16, 2022
Parametric Portfolio Associates LLC
added
6.28
86,000
1,485,000
-%
Aug 16, 2021
PICTET ASSET MANAGEMENT LTD
added
4.06
-235,000
2,123,000
-%
Aug 06, 2021
Smith Asset Management Group LP
unchanged
-
-
1,000
-%

1–10 of 10

Are Funds Buying or Selling ICPT?

Are funds buying ICPT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ICPT
No. of Funds

Unveiling Intercept Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Oct 10, 2023
vanguard group inc
4.95%
2,071,222
SC 13G/A
Jul 10, 2023
vanguard group inc
11.26%
4,693,807
SC 13G/A
Jul 07, 2023
blackrock inc.
10.5%
4,396,970
SC 13G/A
Feb 14, 2023
point72 asset management, l.p.
0.4%
166,300
SC 13G/A
Feb 09, 2023
vanguard group inc
8.78%
3,637,935
SC 13G/A
Feb 02, 2023
state street corp
7.67%
3,175,925
SC 13G/A
Jan 31, 2023
blackrock inc.
7.4%
3,084,833
SC 13G/A
Jan 13, 2023
millennium management llc
2.4%
976,706
SC 13G/A
Oct 12, 2022
point72 asset management, l.p.
4.9%
2,019,983
SC 13G
Oct 11, 2022
fmr llc
-
0
SC 13G/A

Peers (Alternatives to Intercept Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
0.28% 3.53%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.5B
2.0B
2.99% -23.67%
-58.61
9.71
75.20% 68.82%
16.0B
2.5B
8.50% -12.61%
77.77
6.46
13.74% 186.89%
13.8B
3.8B
7.60% -2.83%
18.51
3.66
8.58% 129.81%
MID-CAP
5.2B
107.9M
-8.24% 83.94%
-9.45
48.09
54.84% -28.31%
4.9B
524.1M
-2.95% -55.09%
-11.65
9.28
394.93% 39.61%
3.6B
251.0M
-0.68% -10.56%
-12.18
14.38
73.58% -86.73%
2.9B
240.7M
-4.80% -33.39%
-6.19
12.77
-1.03% -213.92%
2.5B
813.8M
0.54% -38.22%
-1.4K
3.02
56.43% 98.83%
1.9B
996.6M
5.92% 71.39%
-4.85
1.94
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.22% 22.70%
27.15
4.3
60.38% -34.49%
468.2M
881.7K
-2.64% 488.84%
-13.87
481.06
-77.61% 33.36%
221.8M
4.2M
-28.67% 45.58%
-1.78
53.32
-66.30% 48.24%
19.9M
2.1M
16.67% 230.00%
-0.86
7.61
-13.45% 69.54%

Intercept Pharmaceuticals Inc News

Latest updates
Yahoo New Zealand News17 Jun 202410:33 am
Yahoo Canada Shine On13 Jun 202405:26 pm
Investor's Business Daily12 months ago

Intercept Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue6.1%89.0084.0068.0077.0078.0072.0059.0069.0067.0068.0057.0083.0080.0077.0073.0072.0062.0066.0052.0053.0047.00
Cost Of Revenue6.5%0.000.000.000.000.000.000.000.000.000.001.00-2.202.002.001.002.000.001.001.001.001.00
Costs and Expenses2.8%93.0091.0010095.0088.0085.0086.0090.0086.0082.0011144.00135129156161137130136135105
Operating Expenses-------------------136135105
  S&GA Expenses-14.8%45.0053.0058.0055.0043.0040.0038.0040.0041.0044.0059.00-2.0371.0093.0099.0094.0077.0070.0077.0071.0057.00
  R&D Expenses11.3%42.0037.0042.0040.0044.0045.0048.0050.0045.0038.0051.0049.0049.0034.0057.0065.0060.0060.0058.0063.0048.00
Interest Expenses-35.9%2.003.003.004.005.005.007.0015.0014.0013.0012.0012.0012.0012.0012.0012.0012.0010.008.008.008.00
Net Income52.4%-2.79-5.86-32.13-20.82267-7.53-17.28-36.28-3.63-11.09-40.42-52.15-66.47-63.28-92.98-98.16-84.83-71.42-90.27-88.00-64.45
Net Income Margin-128.5%-0.19*0.68*0.70*0.78*0.74*-0.24*-0.26*-0.35*-0.39*-0.59*-0.75*-0.88*-1.07*-1.20*-1.28*-1.37*-1.43*-1.44*-1.62*-1.72*-2.02*
Free Cashflow172.5%17.00-23.00-51.30-4.51-16.9214.00-20.135.004.005.00-55.03-19.71-41.81-15.07-99.16-60.58-46.77-46.24-84.16-52.93-51.58
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-18.9%393485504554559499503527523523520580591637662755802853438509557
  Current Assets-18.5%383471490540545487477508496493488546561607628721769819403482529
    Cash Equivalents-24.6%10313661.0051.0011358.0048.0085.0068.0014693.0058.0045.0051.0041.0070.0063.0094.0055.0043.0059.00
  Inventory-------------------7.007.007.00
  Net PPE-9.3%1.001.001.001.001.001.003.003.004.005.005.006.005.004.005.005.006.007.007.0010.0011.00
Liabilities-23.0%321417437461452868875711679726720747722716697703671678493490461
  Current Liabilities-51.4%91.0018720723022215115116814414514617916316415016214012510811488.00
  Long Term Debt0.1%224224223223223714717540530576568561553546539532525545375371367
    LT Debt, Non Current0.1%224224223223223714717540530576568561553546539532525545375371367
Shareholder's Equity6.4%72.0068.0067.0093.00108----------52.00131175-19.0096.00
  Retained Earnings-0.1%-2,177-2,174-2,169-2,136-2,116-2,383-2,375-2,489-2,453-2,449-2,438-2,398-2,346-2,279-2,216-2,123-2,025-1,940-1,869-1,778-1,690
  Additional Paid-In Capital0.3%2,2572,2502,2442,2382,2322,0162,0082,3092,3002,2492,2412,2342,2182,2022,1862,1762,1572,1161,8151,8001,788
Shares Outstanding0.1%42.0042.0042.0042.0031.0030.0030.0030.0032.0033.0033.0033.0033.0033.0033.0032.0031.0031.0030.0028.0028.00
Float------335---555---1,259---2,028---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations171.6%16,686-23,302-51,597-4,806-16,58814,738-20,1245,1753,5624,847-54,650-17,813-40,478-14,842-98,731-60,484-46,756-45,948-83,425-52,812-51,581
  Share Based Compensation6.2%6,6536,2625,8645,2315,7885,4895,3817,1517,1885,2748,4194,80515,82516,08312,47313,17313,13014,78214,89711,49911,994
Cashflow From Investing-38.3%59,77496,94659,323-54,935331,582-578-14,22015,328-84,25748,31591,34029,84435,09226,06471,81765,88816,475-365,81894,46736,92931,542
Cashflow From Financing-255711.6%-109,999-43.00-254-5,672-257,402-3,924-318-9653,390-224-1,083-156-226442-7535,880892450,5951524401,262
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ICPT Income Statement

2023-09-30
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Condensed Consolidated Statements of Operations    
Revenue$ 88,789$ 77,588$ 240,465$ 208,491
Revenue, Product and Service [Extensible Enumeration]us-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMember
Operating expenses:    
Cost of sales$ 197$ 424$ 604$ 956
Selling, general and administrative45,43843,274156,441121,013
Research and development41,51344,034120,530136,753
Restructuring6,260 6,260 
Total operating expenses93,40887,732283,835258,722
Operating loss(4,619)(10,144)(43,370)(50,231)
Other income (expense):    
Interest expense(1,802)(5,237)(7,423)(18,579)
Loss on extinguishment of debt (91,759) (91,739)
Other income, net3,6613,05310,3262,691
Total other income (expense), net1,859(93,943)2,903(107,627)
Loss from continuing operations(2,760)(104,087)(40,467)(157,858)
(Loss) income from discontinued operations, net of income taxes(30)371,540(320)400,499
Net (loss) income$ (2,790)$ 267,453$ (40,787)$ 242,641
Net income (loss) per common and potential common share (basic and diluted):    
Net loss from continuing operations, Basic (in dollars per share)$ (0.07)$ (3.04)$ (0.97)$ (5.05)
Net loss from continuing operations, Diluted (in dollars per share)(0.07)(3.04)(0.97)(5.05)
Net (loss) income from discontinued operations, Basic (in dollars per share)0.0010.83(0.01)12.81
Net (loss) income from discontinued operations, Diluted (in dollars per share)0.0010.83(0.01)12.81
Net (loss) income, Basic (in dollars per share)(0.07)7.80(0.98)7.76
Net (loss) income, Diluted (in dollars per share)$ (0.07)$ 7.80$ (0.98)$ 7.76
Weighted average common and potential common shares outstanding:    
Basic (in shares)41,79234,29341,73131,262
Diluted (in shares)41,79234,29341,73131,262

ICPT Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 102,736$ 50,517
Restricted cash9205,343
Investment debt securities, available-for-sale219,978435,049
Accounts receivable, net of allowance for credit losses of $65 and $54, respectively32,47926,862
Prepaid expenses and other current assets27,33222,356
Total current assets383,445540,127
Fixed assets, net822987
Inventory2,6496,462
Security deposits1,2751,013
Other assets4,9715,122
Total assets393,162553,711
Current liabilities:  
Accounts payable, accrued expenses and other liabilities89,494116,977
Short-term interest payable1,3513,531
Current portion of long-term debt 109,569
Total current liabilities90,845230,077
Long-term liabilities:  
Long-term debt223,856223,104
Long-term other liabilities6,6167,453
Total liabilities321,317460,634
Commitments and contingencies (Note 15)
Stockholders' equity:  
Common stock par value $0.001 per share; 90,000,000 shares authorized; 41,811,686 and 41,523,337 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively4242
Additional paid-in capital2,256,6812,238,179
Accumulated other comprehensive loss, net(7,203)(8,256)
Accumulated deficit(2,177,675)(2,136,888)
Total stockholders' equity71,84593,077
Total liabilities and stockholders' equity$ 393,162$ 553,711
ICPT
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey.
 CEO
 WEBSITEinterceptpharma.com
 INDUSTRYBiotechnology
 EMPLOYEES341

Intercept Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Intercept Pharmaceuticals Inc? What does ICPT stand for in stocks?

ICPT is the stock ticker symbol of Intercept Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Intercept Pharmaceuticals Inc (ICPT)?

As of Tue Nov 14 2023, market cap of Intercept Pharmaceuticals Inc is 794.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ICPT stock?

You can check ICPT's fair value in chart for subscribers.

What is the fair value of ICPT stock?

You can check ICPT's fair value in chart for subscribers. The fair value of Intercept Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Intercept Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ICPT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Intercept Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ICPT is over valued or under valued. Whether Intercept Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Intercept Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ICPT.

What is Intercept Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Nov 14 2023, ICPT's PE ratio (Price to Earnings) is -12.9 and Price to Sales (PS) ratio is 2.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ICPT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Intercept Pharmaceuticals Inc's stock?

In the past 10 years, Intercept Pharmaceuticals Inc has provided -0.09 (multiply by 100 for percentage) rate of return.